Teladoc Health (TDOC) under pressure after Q4 earnings, JPMorgan analyst Lisa Gill reaffirms neutral rating, price target $11. Revenue estimate of $617.5 million for Q1.

Telemedicine specialist Teladoc Health (TDOC 1.53%) has been a terrible investment over the past three years. Once the ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

(DOCU) on Thursday ...

Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Teladoc Health in a research report issued on Thursday, February 27th. Cantor Fitzgerald ...

Q4 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.88) EPS. Get Teladoc Health alerts: Teladoc Health (NYSE:TDOC – Get Free Report) last released its earnings results on Wednesday ...

Here are four takeaways from digital health’s fourth-quarter earnings season ... Ido Schoenberg during the company’s earnings call. In its annual report, Amwell also noted that it’s not ...

Operator Good afternoon, and thank you, all, for attending the Teladoc Health Q4 2024 earnings call ... I'm pleased to report that we had a very successful implementation season with over 800 ...

PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE ... provide a reasonable baseline for future financial performance. The Fourth Quarter and Full Year 2024 earnings conference ...

the estimate revisions trend for Teladoc: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status ...